Juan Carlos Hernández‐Boluda

ORCID: 0000-0002-4289-3113 · 3 papers in corpus
article 2020
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
·doi:10.1016/j.medcle.2019.11.010

BACKGROUND AND OBJECTIVE MYELOFIBROSIS: is an infrequent chronic myeloproliferative neoplasm. We aimed to describe the clinico-biological characteristics, treatment, and evolutive course of myelofibrosis patients in Spain.Material and metho…

article 2015
Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results
·doi:10.1007/s00277-015-2435-7

The efficacy of danazol was assessed in 50 patients with myelofibrosis and anemia using the recently revised criteria of the International Working Group for Myelofibrosis Research and Treatment. According to them, anemia response (clinical …

article 2000
Danazol treatment of idiopathic myelofibrosis with severe anemia.

BACKGROUND AND OBJECTIVE: Severe anemia is an important problem in patients with idiopathic myelofibrosis (IM). When other therapeutic measures are unsuccessful or not applicable, 40-50% favorable responses are obtained with androgen therap…